New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
Doubts over the safety of Novartis AG’s new anti-VEGF eye drug Beovu (brolucizumab-dbll) have emerged, clouding its current launches in the US and Europe and boosting commercial prospects for other drugs in the anti-VEGF category, notably Bayer AG and Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept).
Concerns emerged over the weekend when the American Society of Retinal Specialists (ASRS) warned members in an email of 14...
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.
The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
